Means for transmembrane delivery of cations of divalent metals, ensuring their inclusion in the intracellular synthesis

 

The invention relates to the field of pharmacy and concerns of normalizing the metabolic function of compensating for the lack of Mg, CA and Zn in the body, acute inflammation of psoriatic and osteoporotic manifestations due to transmembrane delivery of cations of divalent metals, and their inclusion in the intracellular synthesis. The essence of the invention lies in the fact that the proposed tool is a connection in the form of linear or stair dimers, trimers or metal polymers acids of the Krebs cycle and/or amino acids and/or their salts. The technical result - the expansion of the means of ensuring the normalization of metabolic processes associated with trace elements such as Mg, Ca and Zn. 3 C.p. f-crystals, 1 Il., 6 table.

The invention relates to the field of medicine and relates to normalizing the metabolic function of compensating for the lack of Mg, Ca and Zn in the body, acute neurological development, psoriatic and osteoporotic manifestations due to transmembrane delivery of cations of divalent metals and their inclusion in the intracellular synthesis.

It is known that cations of divalent metals play an important role in metabolism. Zinc is armentia systems. Calcium serves as a building block for bones and teeth and is involved in regulation of heart rhythm, blood clotting, muscle contraction. Magnesium activates key enzymes, serves as a conductor of nerve impulses, is involved in the metabolism of proteins and nucleic acids, helps to transport sodium and potassium across cell membranes.

Diseases of various pathophysiological nature would be violated certain processes of intracellular synthesis, normalization which requires the receipt of the relevant metal cations. In this regard, the search means, providing superior delivery is the actual problem in medicine.

The most common sources of divalent metals as their oxides or salts, such as inorganic, such as sulfates, or organic, such as asparaginates. However, most of them have low bioavailability.

In U.S. patent No. 3527798 from 08.09.1970 g Active CIS-form succinate calcium and how you can get" the authors described the connection which is shown in outline form:

where n=2-5.

However, in preclinical trials using the proposed succinate efficacy succinate and turns into biologically inefficient conventional form, having the structure of:

In addition, the above compound has a number of disadvantages:

- provides transport of trace elements into the intracellular space;

- no effect the prevention and treatment of psoriasis;

- no effect the prevention and treatment of osteoporosis;

- mild braking neurological reactions.

Known means of correction of metabolic processes in the cell that represents the applicator wax with suspended metals of variable valence in the ionized state (application EN 94009653 A1, publ. 27.07.1996).

However, this tool has limited use.

Known chelate complexes of amino acids with metals that provide the transport of minerals into the cell (US 6407138 And 18.06.2002).

These complexes is not durable.

The closest is the tool for efficient transfer of metals across cell membranes represent aquaheat in the form of complex compounds of biogenic metal, including ferrous, and one or more biologically active ligands, and one or more coordinating water molecules. As such leagues is 1, publ. 20.07.1998). Basically this tool is available for use in fermentation processes, although it may be useful in therapeutic or prophylactic purposes.

Known means not possess sufficient stability and high transmembrane potential.

The present invention is an expansion of the means on the basis of compounds representing a highly effective components of drugs or biologically active additives to food, which is aimed at expanding the specific biological spectrum of action aimed at stopping the development of neurological, psoriatic and osteoporotic pathological disorders, sleep disorders, depression, increase energy status of the organism, and which also have antioxidant and adaptogenic properties, to normalize the endocrine system.

This object is achieved in that instead allochrony in the molecule acids are linear or stair dimers, trimers and metal polymers acids of the Krebs cycle and/or amino acids, their derivatives and salts. These compounds may be selected from the group comprising: the compound of formula (1)

(R1)ub> - same or different, represent the remainder of the acid of the Krebs cycle, amino acid or lithium, potassium or sodium salt, n=1-20, m=1-50;

the compounds of formula (2)

(R3)to-Me1-(R1)n-Me2-(R2)m,

where Me1and IU2metal from the group of divalent metals CA, Mg and Zn,

R1, R2, R3- same or different, represent the remainder of the acid of the Krebs cycle, amino acid or lithium, potassium or sodium salt, or a residue R a R’, where R’ and R’ are identical or different, represent the remainder of the acid of the Krebs cycle or amino acids, with a+b=2-20,

K=1-20, n=1-20, m=1-50.

The proposed salts of divalent metals was obtained by hydrogenation of the anhydrides of the original acid or the original source of acid on palladium-carbon catalysts containing these divalent metals, at a pressure of 12-35 ATI, with deposition of the resulting product in an aqueous-organic medium or in an organic solvent followed by distillation of the solvent. Compounds containing more than one line managers acid, polycondensates at the stage of precipitation in the solvent.

These compounds possess partial or significant races in order to penetrate into the cytosol of cells, providing the intracellular transport of divalent metals. In addition, the proposed compounds are the derivatives of the major metabolites of the body, actively joining in the reaction of synthesis and energy metabolism at the intracellular level. These properties allow us to solve two problems:

- to deliver divalent metals into the cell,

to ensure their participation in specific Bioorganic synthesis.

The invention is illustrated by the following examples.

Example 1.

Compounds with acids of the Krebs cycle and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi and protivostoyanie properties, antioxidants and adaptogens formula:

Succinate sour:

NOO-N2C-H2With-COO-CA-EA-CH2-CH2-COOH

NOO-N2With-H2C-COO-Mg-OOC-CH2-CH2-COOH

NOO-N2With-H2C-COO-Zn-OOC-CH2-CH2-COOH

NOO-N2C-H2With-COO-CA-EA-CH2-CH2-COONa

CEP-H2With-H2C-COO-Mg-OOC-CH2-CH2-COOK

Li-N2C-H2With-COO-Zn-OOC-CH2-CH2-COONa

Fumarate sour:

Noos-NS=NS-soo-Sa>OOC-HC=HC-COO-Zn-OOC-CH=CH-COONa

Citrate acid:

HOOC-H2C-SLEEP(COOH)-H2C-COO-CA-EA-CH2-SLEEP(COOH)

-CH2-COOH

NOO-N2S-SLEEP(COOH)-H2C-COO-Mg-OOC-CH2-SLEEP(COOH)

-CH2-COOH

NOO-N2S-SLEEP(COOH)-N2With-COO-Zn-OOC-CH2-SLEEP(COOH)

-CH2-COOH

CEP-H2S-SLEEP(COOH)-H2C-COO-CA-EA-CH2-SLEEP(COOH)

-CH2-COONa

LiOOC-H2C-SON(COOH)-H2C-COO-Zn-OOC-CH2-SLEEP(COOH)-CH2

-COOH

Isocitrate sour:

NOO-N2C-CH(COOH)-HE2With-COO-CA-EA-CH2-CH(COOH)-SLEEP2

-COOH

NOO-N2C-CH(COOH)-OH2C-COO-Mg-OOC-CH2-CH(COOH)-SLEEP2

-COOH

NOO-N2C-CH(COOH)-HE2With-COO-Zn-OOC-CH2-CH(COOH)-SLEEP2

-COOH

NaOOC-H2C-CH(COOH)-OH2C-COO-Mg-OOC-CH2-CH(COOH)-SLEEP2

-COOK

-Ketoglutarate sour:

NOO-N2With-H2C-OS-COO-CA-EA-CH2-CH2-CO-COOH

NOO-N2With-H2C-OS-COO-Mg-OOC-CH2-CH2-CO-COOH

NOO-N2With-H2C-OS-COO-Zn-OOC-CH2-CH2-CO-COOH

LiOOC-H2C-H2C-OS-soo-Mg-OOC-CH2-CH2-CO-COONa

NOO-N2With-H2C-OS-soo-Zn-OOC-CH2-CH2-CO-COOK

L-malate sour:

Noos-SON-N2With-b>2-NON-COOH

CEP-SON-N2With-COO-CA-EA-CH2-NON-COOH

NaOOC-HCOH-H2C-COO-Zn-OOC-CH2-NON-COOH

Oxaloacetate sour:

Noos-WITH-H2C-COO-Ca-OOC-CH2-CO-COOH

Noos-CO-N2With-COO-Mg-OOS-CH2-CO-COOH

Noos-CO-N2With-COO-Zn-OOC-CH2-CO-COOH

Noos-CO-N2With-COO-Zn-OOC-CH2-CO-COOLi

Example 2.

Compounds with amino acids and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi and protivostoyanie properties, antioxidants and adaptogens. Connections on the basis of:

L-alaninol:

CH3-CH(NH2)-COO-CA-EA-CH(NH2)-CH3

CH3-CH(NH2)-COO-Mg-OOC-CH(NH2)-CH3

CH3-CH(NH2)-COO-Zn-OOC-CH(NH2)-CH3

L-glycinol:

CH2(NH2)-COO-Ca-OOC-CH2(NH2)

CH2(NH2)-COO-Mg-OOC-CH2(NH2)

CH2(NH2)-COO-Zn-OOC-CH2(NH2)

L-Surinov:

HO-CH(NH2)-COO-Ca-OOC-CH(NH2)-OH

HO-CH(NH2)-COO-Mg-OOC-CH(NH2)-OH

HO-CH(NH2)-COO-Zn-OOC-CH(NH2)-OH

KO-CH(NH2)-COO-Ca-OOC-CH(NH2) OK

LiO-CH(NH2)-COO-Ca-OOC-CH(NH2)-OH

NaO-CH(NH2)-COO-Mg-OOC-CH(NHOOC-CH(NH2)-CH2-SH

HS-CH2-CH(NH2)-COO-Zn-OOC-CH(NH2)-CH2-SH

L-tyrosines:

HO-Ph-CH2-CH(NH2)-OOC-Ca-COO-Ph-CH2-CH(NH2)-OH

HO-Ph-CH2-CH(NH2)-OOC-Mg-COO-Ph-CH2-CH(NH2)-OH

HO-Ph-CH2-CH(NH2)-OOC-Zn-COO-Ph-CH2-CH(NH2)-OH

HO-Ph-CH2-CH(NH2)-OOC-Ca-COO-Ph-CH2-CH(NH2)-ONa

L-aspartic acid:

HOOC-CH2-CH(NH2)-COO-Ca-OOC-CH2-CH(NH2)-COOH

HOOC-CH2-CH(NH2)-COO-Mg-OOC-CH2-CH(NH2)-COOH

HOOC-CH2-CH(NH2)-COO-Zn-OOC-CH2-CH(NH2)-COOH

KOOC-CH2-CH(NH2)-COO-Ca-OOC-CH2-CH(NH2)-COOLi

NaOOC-CH2-CH(NH2)-COO-Ca-OOC-CH2-CH(NH2)-COONa

LiOOC-CH2-CH(NH2)-COO-Ca-OOC-CH2-CH(NH2)-COOLi

L-glutamic acid:

HOOC-CH2-CH2-CH(NH2)-COO-Ca-OOC-CH(NH2)-CH2-CH2-COOH

HOOC-CH2-CH2-CH(NH2)-COO-Mg-OOC-CH(NH2)-CH2-CH2-COOH

HOOC-CH2-CH2-CH(NH2)-COO-Zn-OOC-CH(NH2)-CH2-CH2-COOH

NaOOC-CH2-CH2-CH(NH2)-COO-Ca-OOC-CH(NH2)-CH2-CH2-COOLi

KOOC-CH2-CH2-CH(NH2)-COO-Mg-OOC-CH(NH2)-CH2-CH2-COOH

NaOOC-CH2-CH2-CH(NH2)-COO-Zn-OOC-CH(NH2)-CH2-CH2-COOK

L-lysine:

H2(NH2)

CH2(NH2)-CH2-CH2-CH2-CH(NH2)-COO-Mg-OOC-CH(NH2)-CH2-CH2-

CH2-CH2(NH2)

CH2(NH2)-CH2-CH2-CH2-CH(NH2)-COO-Zn-OOC-CH(NH2)-CH2-CH2-CH2-

CH2(NH2)

Example 3.

Compounds with acids of the Krebs cycle and/or amino acids and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi and protivostoyanie properties, antioxidants and adaptogens formula:

NOO-N2With-H2C-COO-Mg-OOC-CH(NH2)-CH2-CH2-COOH

Noos-CH2-CH(NH2)-COO-Mg-OOC-CH=CH-COOLi

HO-Ph-CH2-CH(NH2)-OOC-Zn-OOC-CH(NH2)-CH2-CH2-CH2-CH2(NH2)

CH3-CH(NH2)-COO-Ca-OOC-CH=CH-COONa

Example 4.

Compounds with acids of the Krebs cycle and/or amino acids and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi, protivostoyanie and anti-inflammatory properties, antioxidants and adaptogens formula:

CH3-C(O)-O-Ph-C-CH2-Cooke

Example 5.

Compounds with acids of the Krebs cycle and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi and protivostoyanie properties, antioxidants and adaptogens formula:

(YAK)2-Sa(UC)2

(YAK)2-Mg-(YAK)2

(YAK)2-Zn-(YAK)2

(YAK)18-Sa(UC)50

PA(UC)2-Sa(UC)25

Li(UC)9-Mg-(YAK)41Li

K(YK)12-Zn-(YAK)29

where YAK-radical of succinic acid,

(FC)2-Sa(FC)4

(FC)2MD(FC)4

(FC)2-Zn-(FC)4

(FC)12-Mg-(FC)46

(FC)2-Sa(FC)4Li

Na (FC)6-Mg-(FC)8PA

where FC is the radical fumaric acid,

(LK)2-Sa-(LA)2

(LK)2MD(LK)2

(LK)2-Zn-(LK)2

(LK)12-Sa-(LA)50

(LK)8-Zn-(LK)12

Na(LK)20-Mg-(AK)29

where LK is the radical of citric acid,

(Ilk)2-Sa(ilk)2

(Ilk)2-Mg-(ilk)12

(Ilk)5-Zn-(ilk)22

Na(ilk)2-Mg-(ilk)22

Li(ilk)2-Sa(ilk)2Li

K(ilk)16-Mg-(ilk)50

where ilk - RA is (K)22

PA(SCC)6-Sa(SCC)8

where SCC - radical Ketoglutarate acid,

(YAK)5(MK)2-Sa(MC)3(YAK)7

(YAK)5(MK)2-Sa(MC)3(FC)16(YAK),

where MK is the radical of malonic acid.

Example 6.

Compounds with amino acids and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi and protivostoyanie properties, antioxidants and adaptogens formula:

(AK)n-Sa(AK)m

(AK)n-Mg-(AK)m

(AK)n-Zn-(AK)m

where (AK)nand (AK)m- fragments of proteins with chain length up to 20 and 50 units, respectively.

Example 7.

Compounds with acids of the Krebs cycle and/or amino acids and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi and protivostoyanie properties, antioxidants and adaptogens formula:

(YAK)2(AK)n-Zn-(AK)m

(FC)(AK)n-Sa(AK)m(FC)PA

Example 8.

Compounds with acids of the Krebs cycle and/or amino acids and/or their sodium, potassium is daysie protivostoyanie, protivopoloznymi and anti-inflammatory properties, antioxidants and adaptogens formula:

(AC)(FC)12MD(FC)46(AC)

(YAK)2(AK)n-Zn-(AK)m(AC)

(YAK)2(AK)n-Zn-(AK)m(AC),

where AC - radical acetilsalicilico acid.

Example 9.

Compounds with acids of the Krebs cycle and/or amino acids and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi and protivostoyanie properties, antioxidants and adaptogens formula:

K(FC)12-Ca-(AK)7-Mg-(FC)46

(AK)18-Ca-(AK)7-Mg-(YAK)26Na

Li(AK)18-Zn-(LK)7-Mg-(YAK)22Na

Example 10.

Compounds with acids of the Krebs cycle and/or amino acids and/or their sodium, potassium or lithium salts with transporting properties, correctors of the endocrine and nervous systems, with protivopoloznymi, protivostoyanie and anti-inflammatory properties, antioxidants and adaptogens formula:

(AC)(AC)18-Sa(AK)7MD(UC)26PA

Li(AK)18-Zn-(LK)7-Mg-(YAK)22(AC)

where AC - radical acetilsalicilico acid

P the listed compounds synthesized in small quantities with the use of radioactive isotopes of divalent metals. The samples were fed to adult animals (nonlinear mice of the same age and average weight). Animals were monitored for 20 days, with all the selection of animals was collected individually and measured their total activity. After observing animals were scored and conducted separate control tissues and bones of the residual radioactivity. For different samples of residual radioactive metals in the tissues was 62-83 wt.%. From 70 to 95 wt.% calcium and 25-45 wt.% magnesium was in the bone tissue of animals, 95-100 wt.% zinc was in the soft tissues (table 1).

Psoriasis varies not only cellular composition and thickness of the epidermis, but the type of collagen fibers. For chronic psoriatic process is characterized by cellular infiltration, intra - and extracellular edema, 6-10-fold hypertrophy of the epidermis with the destruction of the keratin layer and, as a consequence, the appearance of collagen fibers, which are an integral indicator of psoriasis and characteristic phenomenon for the elderly. For the study for each group of compounds described in examples 1-10 was provided for 14 samples of the skin of the tail of rats of different ages:

1) samples 1-5 - old rats, p is uppy;

3) samples 11-14 young rats from the control group. All samples were processed by standard methods including the steps of alkaline treatment, neutralization, extraction and purification of collagen. The selected collagen was dissolved in 0.5 M acetic acid. By the method of differential scanning microcalorimetry studies have been conducted of the melting process of the collagen fibrils. The measurements were carried out on a differential scanning microcalorimeter DASM-4A (NGOs "Bioprobes") at a heating rate of 1 deg/min and a gauge pressure of 2 ATM. The experimental data were processed using the program Origin.

Was defined temperature range in which melting occurs collagen (T1/2- width of the peak of the phase transition at half the height characterizes cooperatively phase transition is closely related to the number of intramolecular bonds in the collagen fibrils). The data presented in table.6.

Weight characteristics of the femur in the Mature group (6-7 months

Analysis of the data presented in the table leads to the conclusion that in the group of old rats (age 15 months) the impact of the proposed salts led to changes in internal state is the shaft.

These data show the possibility of using these compounds as protivostoyavshih, protivopolozhnyh funds. The proposed compounds were tested on rats with chronic stress and when tested in the open field. Psychomotor behavior log and evaluated on a scale of Morrison Podolsky as the appearance of the following pathological motor acts: 1. Clonic convulsions, 2. Aggressive behavior, 3. Tremor, 4. Stereotyped movements, 5. Poor coordination, 6. Catalepsy-like activity, 7. Dyskinesia type of "wet dog", 8. Voice responses, 9. Hyperactivity and normal behavior (sleep, exploration, grooming, washing, brushing). The behavior observed for 20 minutes for every minute to be assessed (+ or -) of the listed symptoms. In the control group animals showed steps 2-5, which is typical of the behavior of laboratory rats in open field. In the experimental group animals showed research activity, and in some cases even grooming, which indicates the high adaptogenes proposed salt.

Thus, shows a significant reduction of activity neurological reactions in rats.

Protivo is shown the dynamics of the content of leukocytes in peripheral blood, taken in the wound (flowing blood) in the development of local inflammation (non-sterile wound: incision, then sewed):

control - pink line - number 2

experience (accept connections on examples 4, 8 and 10) - row 1 - blue line.

Abscissa:

1. Reference level (average 6 rats).

2, 3, 4 the development of inflammation (3, 5 and 10 days).

It is seen that the intake of the proposed salt leukocytosis less and quickly fizzles. Without salts increase of leukocytosis is observed up to higher numbers, and after 10 days will not be returned to normal.

About the same dynamics ESR (erythrocyte sedimentation rate from 4 to 15 mm).

Normal C-reactive protein is simply not available. With the development of local inflammation in monitoring the quality is identified on the second day and ceases to depend on the 6th day. In the experience of C-reactive protein was determined qualitatively by the end of the first - the beginning of the second day of inflammation and stopped to decide for 3-4 days.

The data obtained indicate the presence of anti-inflammatory activity.

Connections can be made in any acceptable dosage forms received conventional pharmaceutical methods.

All these compounds (synthesized without outcasts GLP requirements and health Ministry. Particularly effective compounds were in osteoporosis, psoriasis, patients with neurological disorders and inflammatory diseases. Confirmed the absence of genotoxicity and food security. Side effects are not identified.

Claims

1. Means for transmembrane delivery of cations of divalent metals, ensuring their inclusion in the intracellular synthesis, characterized in that it is a connection in the form of linear or stair dimers, trimers or metal polymers acids of the Krebs cycle, and/or amino acids and/or their salts selected from the group including:

the compounds of formula (1)

(R1)n-IU-(R2)m,

where Me is a metal from the group of divalent metals CA, Mg and Zn;

R1and R2- same or different, represent the remainder of the acid of the Krebs cycle, amino acid or lithium, potassium or sodium salt;

n=1-20, m=1-50,

with the IU1and IU2metal from the group of divalent metals CA, Mg and Zn;

R1, R2, R3- same or different, represent the remainder of the acid of the Krebs cycle, amino acid or lithium, potassium or sodium salt, or a residue R’aRinwhere R’ and R’ are identical or different, represent the remainder of the acid of the Krebs cycle or amino acids, with a+b=2-20;

K=1-20, n=1-20, m=1-50.

2. Means under item 1, characterized in that it is used in osteoporosis or psoriasis.

3. Means under item 1, characterized in that it is used as adaptogene.

4. Means under item 1, characterized in that it is used in inflammatory processes.

 

Same patents:

The invention relates to a method of reducing the abuse of an oral dosage form of an opioid analgesic, which analgesic effective amount of orally active opioid agonist is combined with an opioid antagonist in the dosage form for oral administration, and will require at least a two-stage extraction to highlight the opioid agonist and the number entered in the dosage form of an opioid antagonist sufficient to inhibit the action of opioid co-extraction of the opioid agonist and parenteral

The invention relates to benzoylpyridine formula I

where R(1) denotes CF3; one of the substituents R(2) and R(3) represents hydrogen; and the other of the substituents R(2) or R(3) represents-CH(CH3)-CH2OH; R(4) denotes methyl, and their pharmaceutically acceptable salts

The invention relates to the field of medicine and relates to new N-pinakamaraming tryptophanase of dipeptides of the formula

C6H5-(CH2)n-CO-NH-(CH2)m-CO-X-Trp-R,

where n=1-5;

m=1-3;

X=L or D-configuration;

R=OH, OCH3OC2H5, NH2, NHCH3,

as well as pharmaceutical compositions containing them

The invention relates to the field of medicine and relates to new N-pinakamaraming tryptophanase of dipeptides of the formula

C6H5-(CH2)n-CO-NH-(CH2)m-CO-X-Trp-R,

where n=1-5;

m=1-3;

X=L or D-configuration;

R=OH, OCH3OC2H5, NH2, NHCH3,

as well as pharmaceutical compositions containing them

The invention relates to the field of medicine and relates to new N-pinakamaraming tryptophanase of dipeptides of the formula

C6H5-(CH2)n-CO-NH-(CH2)m-CO-X-Trp-R,

where n=1-5;

m=1-3;

X=L or D-configuration;

R=OH, OCH3OC2H5, NH2, NHCH3,

as well as pharmaceutical compositions containing them

The invention relates to medicine and relates to a pharmaceutical composition intended for the treatment of alcohol and drug dependence, comprising a therapeutically effective amount of (i) an opioid antagonist and (ii) a modulator of the NMDA receptor complex, and the pharmaceutical kit comprising (i) an opioid antagonist and (ii) a modulator of the NMDA receptor complex
The invention relates to medicine, in particular therapy, and can be used in medical institutions for the treatment of pain in patients with chronic somatic diseases

The invention relates to novel alkyl-piperazinil benzoxazolinone and alkyl-piperidinyl benzoxazolinone derivative of the formula (I), where S1is hydrogen; Z is =C or N; R1, R2and R4independently represent hydrogen, Q is methyl, ethyl or cyclopropylmethyl, and their salts and prodrugs

The invention relates to a new-aryl-N-alkylsilanes formula I or II, pharmaceutical compositions based on them, the method of inhibiting neurodegenerative diseases, in particular diseases such as Alzheimer's disease, methods of treatment of autoimmune diseases and ways to prevent the occurrence of autoimmune and inflammatory conditions of the nervous system in mammals using the compounds I or II
The invention relates to the treatment of non-insulin-dependent diabetes of adults (diabetes type II), in particular to the treatment of type II diabetes by the introduction of chromium picolinate and Biotin

The invention relates to the field of medicine

The invention relates to the field of pharmacology, and relates to pharmaceutical preparations for the treatment of gastritis, reflux esophagitis, duodenitis, dyspepsia and ulcers
The invention relates to medicine, namely oncodermatology, medical cosmetology, pharmacology

The invention relates to medicine, in particular to create a composition based on natural products with antovic and Antiherpes activity

The invention relates to new compositions of chemical compositions, namely the composition of the ten natural amino acids with four trace elements, sodium and potassium, which possess antiarrhythmic activity, and may find application in medical practice

The invention relates to new compositions of chemical compositions, namely the composition of the ten natural amino acids with four trace elements and calcium, which has anticancer, antidepressant and anti-arrhythmic activity and may find application in medicine
The invention relates to a complex homeopathic medicines and can be used for treatment of neurotic disorders in the early stages of atherosclerosis in elderly and senile age

The invention relates to chemical-pharmaceutical industry, namely the production of medicinal and nutritional means to compensate for the deficiency of iron, copper and vitamins in the body, mainly children
Up!